Advanced Patient Monitoring Systems

Manufacturers of patient monitoring equipment are responding to a challenging hospital environment. They're providing advanced portable and telemetry monitoring systems that enable the continuous monitoring of critically ill patients, regardless of their location within the hospital, and often at a lower cost than could be achieved using traditional bedside systems. Portable and telemetry systems are two of the highest growth segments in the US patient monitoring market, according to Windhover Information/Medtech Insight's recently published report, US Markets for Patient Monitoring Products, which forecasts compound annual growth rates (CAGR) of 8.5% and 13.0%, respectively, in these segments through 2012.

It’s no news that hospitals are under pressure; the demand for critical care is growing dramatically as the average acuity of hospitalized patients rises with the increasing elderly population. At the same time, there is an acute shortage of registered nurses. Fortunately, this is exactly the sort of problem that lends itself to technological solutions, and manufacturers of patient monitoring equipment are responding to this challenging environment by providing advanced portable and telemetry monitoring systems that enable hospitals to provide the continuous monitoring of critically ill patients, regardless of their location within the hospital, and often at a lower cost than could be achieved using traditional bedside systems.

Portable and telemetry systems are two of the highest growth segments in the US patient monitoring market, according to Windhover Information/Medtech Insight’s recently published report, US Markets for Patient Monitoring Products, which forecasts compound annual growth rates (CAGR) of 8.5% and 13.0%, respectively, in these segments through 2012

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Synchron And Apple Team Up To Use ‘Mind-Thought Connection’ To Control iPhones, iPads

 
• By 

Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

A Deregulated Medtech Sector Could Flourish In Merz’s Industry-Friendly Germany

 
• By 

Less bureaucracy, no more national supply chain law, framework agreements and competition for direct reimbursement of medtech innovations are among the positive changes the local medtech industry might expect as Germany’s new government gets down to work. Life sciences lawyer Gunnar Sachs offers a view from the ground.